Polyamines in drug discovery: From the universal template approach to the multitarget-directed ligand design strategy

Journal of Medicinal Chemistry

Volumn 53, Issue 16, 2010, Pages 5906-5914

  Melchiorre, Carlo ^a   Bolognesi, Maria Laura ^a   Minarini, Anna ^a   Rosini, Michela ^a   Tumiatti, Vincenzo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BENEXTRAMINE; BETA SECRETASE INHIBITOR; CHOLINESTERASE INHIBITOR; DMR 44; DONEPEZIL; GALANTAMINE; IODINE DERIVATIVE; LIGAND; MEMOQUIN; METHOCTRAMINE; MR 44; MUSCARINIC M2 RECEPTOR ANTAGONIST; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; NOOTROPIC AGENT; POLYAMINE; RIVASTIGMINE; SPERMINE; SPIROTRAMINE; TACRINE; TRIPITRAMINE; UBIQUINONE DERIVATIVE; UNCLASSIFIED DRUG;

BINDING AFFINITY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; NONHUMAN; REVIEW; STOICHIOMETRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; DRUG DESIGN; DRUG DISCOVERY; LIGANDS; MODELS, ANIMAL; POLYAMINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77955904672     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100293f     Document Type: Review

References (71)

1. Keseru, G. M.; Makara, G. M. Hit discovery and hit-to-lead approaches Drug Discovery Today 2006, 11, 741-748
2. Overington, J. P.; Al-Lazikani, B.; Hopkins, A. L. How many drug targets are there? Nat. Rev. Drug Discovery 2006, 5, 993-996
3. Hopkins, A. L.; Mason, J. S.; Overington, J. P. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 2006, 16, 127-136
4. Hopkins, A. L. Network pharmacology: the next paradigm in drug discovery Nat. Chem. Biol. 2008, 4, 682-690
5. Bolognesi, M. L.; Matera, R.; Minarini, A.; Rosini, M.; Melchiorre, C. Alzheimer's disease: new approaches to drug discovery Curr. Opin. Chem. Biol. 2009, 13, 303-308
6. Youdim, M. B.; Buccafusco, J. J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders Trends Pharmacol. Sci. 2005, 26, 27-35
7. Morphy, R.; Rankovic, Z. Designing multiple ligands: medicinal chemistry strategies and challenges Curr. Pharm. Des. 2009, 15, 587-600
8. Millan, M. J. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs Neurotherapeutics 2009, 6, 53-77
9. Morphy, R.; Rankovic, Z. Fragments, network biology and designing multiple ligands Drug Discovery Today 2007, 12, 156-160
10. Morphy, R.; Rankovic, Z. The physicochemical challenges of designing multiple ligands J. Med. Chem. 2006, 49, 4961-4970
11. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 2005, 48, 6523-6543
12. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands Drug Discovery Today 2004, 9, 641-651
13. Millan, M. J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application Pharmacol. Ther. 2006, 110, 135-370
14. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases J. Med. Chem. 2008, 51, 347-372
15. Zhang, H. Y. One-compound-multiple-targets strategy to combat Alzheimer's disease FEBS Lett. 2005, 579, 5260-5264
16. Melchiorre, C.; Angeli, P.; Brasili, L.; Giardinà, D.; Pigini, M.; Quaglia, W. Polyamines: a possible "passe-partout" for receptor characterization Actual. Chim. Ther. 1988, 149-168
17. Bolognesi, M. L.; Minarini, A.; Budriesi, R.; Cacciaguerra, S.; Chiarini, A.; Spampinato, S.; Tumiatti, V.; Melchiorre, C. Universal template approach to drug design: polyamines as selective muscarinic receptor antagonists J. Med. Chem. 1998, 41, 4150-4160
18. Melchiorre, C.; Yong, M. S.; Benfey, B. G.; Belleau, B. Molecular properties of the adrenergic α-receptor. 2. Optimum covalent inhibition by two different prototypes of polyamine disulfides J. Med. Chem. 1978, 21, 1126-1132
19. Melchiorre, C. Tetramines disulfides: a new tool in α-adrenergic pharmacology Trends Pharmacol. Sci. 1981, 2, 209-211
20. Benfey, B. G.; Brasili, L.; Melchiorre, C.; Belleau, B. Potentiation and inhibition of nicotinic effects on striated muscle by the tetramine disulfide benextramine Can. J. Physiol. Pharmacol. 1980, 58, 984-988
21. Benfey, B. G.; Yong, M. S.; Belleau, B.; Melchiorre, C. Cardiac muscarinic blocking and atropinic blocking effects of a tetramine disulfide and α-adrenoceptor blocking activity Can. J. Physiol. Pharmacol. 1979, 57, 41-47
22. Doughty, M. B.; Chu, S. S.; Miller, D. W.; Li, K.; Tessel, R. E. Benextramine: a long-lasting neuropeptide Y receptor antagonist Eur. J. Pharmacol. 1990, 185, 113-114
23. Melchiorre, C.; Romualdi, P.; Bolognesi, M. L.; Donatini, A.; Ferri, S. Binding profile of benextramine at neuropeptide Y receptor subtypes in rat brain areas Eur. J. Pharmacol. 1994, 265, 93-98
24. DeSimone, R. W.; Currie, K. S.; Mitchell, S. A.; Darrow, J. W.; Pippin, D. A. Privileged structures: applications in drug discovery Comb. Chem. High Throughput Screening 2004, 7, 473-494
25. Nicolaou, K. C.; Pfefferkorn, J. A.; Roecker, A. J.; Cao, G.-Q.; Barluenga, S.; Mitchell, H. J. Natural product-like combinatorial libraries based on priviliged structures. 1. General principles and solid-phase synthesis of benzopyrans J. Am. Chem. Soc. 2000, 122, 9939-9953
26. Fiori, L. M.; Turecki, G. Implication of the polyamine system in mental disorders J. Psychiatry Neurosci. 2008, 33, 102-110
27. Seiler, N.; Raul, F. Polyamines and apoptosis J. Cell. Mol. Med. 2005, 9, 623-642
28. Gilad, G. M.; Gilad, V. H. Overview of the brain polyamine-stress- response: regulation, development, and modulation by lithium and role in cell survival Cell. Mol. Neurobiol. 2003, 23, 637-649
29. Tabor, C. W.; Tabor, H. Polyamines Annu. Rev. Biochem. 1984, 53, 749-790
30. Larque, E.; Sabater-Molina, M.; Zamora, S. Biological significance of dietary polyamines Nutrition 2007, 23, 87-95
31. Kusano, T.; Berberich, T.; Tateda, C.; Takahashi, Y. Polyamines: essential factors for growth and survival Planta 2008, 228, 367-381
32. Igarashi, K.; Kashiwagi, K. Modulation of cellular function by polyamines Int. J. Biochem. Cell Biol. 2010, 42, 39-51
33. Williams, K. Modulation and block of ion channels: a new biology of polyamines Cell. Signalling 1997, 9, 1-13
34. Masuko, T.; Kusama-Eguchi, K.; Sakata, K.; Kusama, T.; Chaki, S.; Okuyama, S.; Williams, K.; Kashiwagi, K.; Igarashi, K. Polyamine transport, accumulation, and release in brain J. Neurochem. 2003, 84, 610-617
35. Kaur, N.; Delcros, J. G.; Imran, J.; Khaled, A.; Chehtane, M.; Tschammer, N.; Martin, B.; Phanstiel, O. t. A comparison of chloroambucil- and xylene-containing polyamines leads to improved ligands for accessing the polyamine transport system J. Med. Chem. 2008, 51, 1393-1401
36. Agostinelli, E.; Marques, M. P.; Calheiros, R.; Gil, F. P.; Tempera, G.; Viceconte, N.; Battaglia, V.; Grancara, S.; Toninello, A. Polyamines: fundamental characters in chemistry and biology Amino Acids 2010, 38, 393-403
37. Soulet, D.; Gagnon, B.; Rivest, S.; Audette, M.; Poulin, R. A fluorescent probe of polyamine transport accumulates into intracellular acidic vesicles via a two-step mechanism J. Biol. Chem. 2004, 279, 49355-49366
38. Casero, R. A., Jr. ; Marton, L. J. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases Nat. Rev. Drug Discovery 2007, 6, 373-390
39. Belting, M.; Mani, K.; Jonsson, M.; Cheng, F.; Sandgren, S.; Jonsson, S.; Ding, K.; Delcros, J. G.; Fransson, L. A. Glypican-1 is a vehicle for polyamine uptake in mammalian cells: a pivital role for nitrosothiol-derived nitric oxide J. Biol. Chem. 2003, 278, 47181-47189
40. Wallace, H. M.; Fraser, A. V.; Hughes, A. A perspective of polyamine metabolism Biochem. J. 2003, 376, 1-14
41. Casero, R. A., Jr. ; Woster, P. M. Recent advances in the development of polyamine analogues as antitumor agents J. Med. Chem. 2009, 52, 4551-4573
42. Estrada, G.; Villegas, E.; Corzo, G. Spider venoms: a rich source of acylpolyamines and peptides as new leads for CNS drugs Nat. Prod. Rep. 2007, 24, 145-161
43. Stromgaard, K.; Jensen, L. S.; Vogensen, S. B. Polyamine toxins: development of selective ligands for ionotropic receptors Toxicon 2005, 45, 249-254
44. Li, J.; Doyle, K. M.; Tatlisumak, T. Polyamines in the brain: distribution, biological interactions, and their potential therapeutic role in brain ischaemia Curr. Med. Chem. 2007, 14, 1807-1813
45. Supattapone, S.; Piro, J. R.; Rees, J. R. Complex polyamines: unique prion disaggregating compounds CNS Neurol. Disord.: Drug Targets 2009, 8, 323-328
46. Senanayake, M. D.; Amunugama, H.; Boncher, T. D.; Casero, R. A.; Woster, P. M. Design of polyamine-based therapeutic agents: new targets and new directions Essays Biochem. 2009, 46, 77-94
47. Boncher, T.; Bi, X.; Varghese, S.; Casero, R. A., Jr. ; Woster, P. M. Polyamine-based analogues as biochemical probes and potential therapeutics Biochem. Soc. Trans. 2007, 35, 356-363
48. 13C-NMR chemical shift assignments of spermidine, spermine, and homologs Biophys. Chem. 1983, 17, 67-74
49. Melchiorre, C.; Cassinelli, A.; Quaglia, W. Differential blockade of muscarinic receptor subtypes by polymethylene tetraamines. Novel class of selective antagonists of cardiac M-2 muscarinic receptors J. Med. Chem. 1987, 30, 201-204
50. Minarini, A.; Bolognesi, M. L.; Budriesi, R.; Canossa, M.; Chiarini, A.; Spampinato, S.; Melchiorre, C. Design, synthesis, and biological activity of methoctramine-related tetraamines bearing an 11-acetyl-5,11-dihydro-6 H -pyrido[2,3- b ][1,4] benzodiazepin-6-one moiety: structural requirements for optimum occupancy of muscarinic receptor subtypes as revealed by symmetrical and unsymmetrical polyamines J. Med. Chem. 1994, 37, 3363-3372
51. Melchiorre, C.; Minarini, A.; Spampinato, S.; Tumiatti, V. Design, synthesis and biological activity of some tetraamines related to methoctramine and 4-DAMP Bioorg. Med. Chem. Lett. 1995, 5, 785-790
52. Melchiorre, C.; Minarini, A.; Angeli, P.; Giardina, D.; Gulini, U.; Quaglia, W. Polymethylene tetraamines as muscarinic receptor probes Trends Pharmacol. Sci. 1989, Suppl.) 55-59
53. Rosini, M.; Bixel, M. G.; Marucci, G.; Budriesi, R.; Krauss, M.; Bolognesi, M. L.; Minarini, A.; Tumiatti, V.; Hucho, F.; Melchiorre, C. Structure-activity relationships of methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. 2. Role of polymethylene chain lengths separating amine functions and of substituents on the terminal nitrogen atoms J. Med. Chem. 2002, 45, 1860-1878
54. Zini, M.; Passariello, C. L.; Gottardi, D.; Cetrullo, S.; Flamigni, F.; Pignatti, C.; Minarini, A.; Tumiatti, V.; Milelli, A.; Melchiorre, C.; Stefanelli, C. Cytotoxicity of methoctramine and methoctramine-related polyamines Chem.-Biol. Interact. 2009, 181, 409-416
55. Ferri, C. P.; Prince, M.; Brayne, C.; Brodaty, H.; Fratiglioni, L.; Ganguli, M.; Hall, K.; Hasegawa, K.; Hendrie, H.; Huang, Y.; Jorm, A.; Mathers, C.; Menezes, P. R.; Rimmer, E.; Scazufca, M. Global prevalence of dementia: a Delphi consensus study Lancet 2005, 366, 2112-2117
56. Roberson, E. D.; Mucke, L. 100 years and counting: prospects for defeating Alzheimer's disease Science 2006, 314, 781-784
57. Cavalli, A.; Bolognesi, M. L.; Capsoni, S.; Andrisano, V.; Bartolini, M.; Margotti, E.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. A small molecule targeting the multifactorial nature of Alzheimer's disease Angew. Chem., Int. Ed. 2007, 46, 3689-92
58. Bolognesi, M. L.; Banzi, R.; Bartolini, M.; Cavalli, A.; Tarozzi, A.; Andrisano, V.; Minarini, A.; Rosini, M.; Tumiatti, V.; Bergamini, C.; Fato, R.; Lenaz, G.; Hrelia, P.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease J. Med. Chem. 2007, 50, 4882-4897
59. Andrisano, V.; Bartolini, M.; Bolognesi, M. L.; Cavalli, A.; Melchiorre, C.; Recanatini, M. 2,5-Bis-diamine-[1,4]-benzoquinonic derivatives, Useful for the Teatment of Alzheimer's Disease, Method for Preparing Them and Intermediates of Said Method. U.S. Patent 7,589,219 B2, 2009.
60. Melchiorre, C.; Andrisano, V.; Bolognesi, M. L.; Budriesi, R.; Cavalli, A.; Cavrini, V.; Rosini, M.; Tumiatti, V.; Recanatini, M. Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease J. Med. Chem. 1998, 41, 4186-4189
61. Inestrosa, N. C.; Alvarez, A.; Perez, C. A.; Moreno, R. D.; Vicente, M.; Linker, C.; Casanueva, O. I.; Soto, C.; Garrido, J. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme Neuron 1996, 16, 881-891
62. Campos, E. O.; Alvarez, A.; Inestrosa, N. C. Brain acetylcholinesterase promotes amyloid-beta-peptide aggregation but does not hydrolyze amyloid precursor protein peptides Neurochem. Res. 1998, 23, 135-140
63. Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies Biochem. Pharmacol. 2003, 65, 407-416
64. Gutzmann, H.; Hadler, D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study J. Neural Transm., Suppl. 1998, 54, 301-310
65. Hirai, K.; Hayako, H.; Kato, K.; Miyamoto, M. Idebenone protects hippocampal neurons against amyloid beta-peptide-induced neurotoxicity in rat primary cultures Naunyn Schmiedeberg's Arch. Pharmacol. 1998, 358, 582-585
66. Ono, K.; Hasegawa, K.; Naiki, H.; Yamada, M. Preformed beta-amyloid fibrils are destabilized by coenzyme Q10 in vitro Biochem. Biophys. Res. Commun. 2005, 330, 111-116
67. Moreira, P. I.; Siedlak, S. L.; Aliev, G.; Zhu, X.; Cash, A. D.; Smith, M. A.; Perry, G. Oxidative stress mechanisms and potential therapeutics in Alzheimer disease J. Neural Transm. 2005, 112, 921-932
68. SantaCruz, K. S.; Yazlovitskaya, E.; Collins, J.; Johnson, J.; DeCarli, C. Regional NAD(P)H:quinone oxidoreductase activity in Alzheimer's disease Neurobiol. Aging 2004, 25, 63-69
69. Melnikova, I. Therapies for Alzheimer's disease Nat. Rev. Drug Discovery 2007, 6, 341-342
70. Capsoni, S.; Cattaneo, A. On the molecular basis linking nerve growth factor (NGF) to Alzheimer's disease Cell. Mol. Neurobiol. 2006, 26, 619-633
71. Bolognesi, M. L.; Cavalli, A.; Melchiorre, C. Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease Neurotherapeutics 2009, 6, 152-162